

Rx&D and the Biopharmaceutical Investment Fund (BIF)

Helping to Build a Strong and Healthy Ontario

Canada's Research-Based Pharmaceutical Companies (Rx&D) is the national association representing over 22,000 men and women who work for more than 50 research-based pharmaceutical companies in Canada.

Member companies share a single primary objective: to discover new medicines and vaccines that improve the quality of health care available for every Canadian.

A Healthy Ontario

- Effective use of new medicines and vaccines has reduced health care costs by a factor of 7 to 1 through the avoidance of invasive procedures, reducing hospital visits and assisting in chronic disease management (F. Lichtenberg).
- Our discoveries improve and save lives. For example, there has been a sharp decline in child cancer mortality rates over the past 30 years. Today, 80% of children with leukemia are still alive five years after diagnosis.
- Over 80 % of heart attack patients admitted to hospital survive.
- On average each year, about 40,000 Ontario patients benefit from clinical trials which provide access to innovative therapies.

A Stronger Ontario Economy

- Annually member companies inject about \$2 billion into Ontario's economy.
- Member companies of Canada's research-based pharmaceutical community employ over 9,000 men and women in Ontario. When employment created in other sectors are taken into account, we generate about 35,000 jobs in the Ontario economy overall.
- Rx&D members have over \$535 million invested in land, facilities and equipment throughout the province as of 2006.

An Innovative Ontario

- In 2007, Rx&D member companies invested more than \$500 million in research and development in Ontario. More than \$100 million was invested in public research institutions including hospitals and universities.
- Over the past 20 years, our community has invested more than \$1.2 billion in universities and hospitals.
- Investment in research and development by the innovative pharmaceutical community has increased by more than 650 % from 1988 to 2006.

- 30 -

For further information:

François Lessard

Communications

Telephone: (613) 236-0455

E-mail: fllessard@canadapharma.org